{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:13:50Z","timestamp":1794654830153,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.toxlet.2026.111893","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:51:10Z","timestamp":1775789470000},"page":"111893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Influence of hepatic steatosis on antiseizure drug metabolism: in vitro evidence from differentiated HepaRG cells"],"prefix":"10.1016","volume":"419","author":[{"given":"Valentin","family":"Plissonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gicquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma-Rose","family":"Legrand Brault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Massart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Le Dar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2026.111893_bib1","unstructured":"Organisation Mondiale de la Sant\u00e9. Ob\u00e9sit\u00e9 et surpoids 2025. Accessed July 15, 2025. \u3008https:\/\/www.who.int\/fr\/health-topics\/obesity\u3009."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1467-789X.2004.00126.x","article-title":"Hepatic steatosis in obese patients: clinical aspects and prognostic significance","volume":"5","author":"Festi","year":"2004","journal-title":"Obes. Rev."},{"issue":"5","key":"10.1016\/j.toxlet.2026.111893_bib3","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.toxlet.2026.111893_bib4","series-title":"Fatty Liver Disease","first-page":"23","article-title":"The Epidemiology and Risk Factors of NASH","author":"Mccullough","year":"2004"},{"issue":"10","key":"10.1016\/j.toxlet.2026.111893_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinre.2011.04.015","article-title":"Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role","volume":"35","author":"Aubert","year":"2011","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"issue":"5","key":"10.1016\/j.toxlet.2026.111893_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.toxlet.2026.111893_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jhep.2012.12.018","article-title":"Drug-induced liver injury in obesity","volume":"58","author":"Fromenty","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.toxlet.2026.111893_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biochi.2020.08.018","article-title":"Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?","volume":"179","author":"Ferron","year":"2020","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.toxlet.2026.111893_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17425255.2017.1314461","article-title":"Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease","volume":"13","author":"Dietrich","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.111.039925","article-title":"UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis","volume":"40","author":"Xu","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.toxlet.2026.111893_bib11","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1152\/physrev.2001.81.4.1499","article-title":"Physiological roles and regulation of mammalian sulfate transporters","volume":"81","author":"Markovich","year":"2001","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.112.048439","article-title":"Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease","volume":"41","author":"Hardwick","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.yebeh.2013.05.012","article-title":"Obesity in adults with epilepsy","volume":"28","author":"Janousek","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.toxlet.2026.111893_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2021.07.019","article-title":"Associations of overweight and obesity with drug-resistant epilepsy","volume":"92","author":"Chen","year":"2021","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.toxlet.2026.111893_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.nrl.0000256353.14257.7c","article-title":"A new look at the second-generation antiepileptic drugs: a decade of experience","volume":"13","author":"LaRoche","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.toxlet.2026.111893_bib17","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed November 24, 2025. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/\u3009."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions - principles and clinical implications","volume":"8","author":"I. Johannessen","year":"2010","journal-title":"CN"},{"issue":"17","key":"10.1016\/j.toxlet.2026.111893_bib19","doi-asserted-by":"crossref","first-page":"9582","DOI":"10.3390\/ijms22179582","article-title":"Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients","volume":"22","author":"Kara\u017aniewicz-\u0141ada","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.toxlet.2026.111893_bib20","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s11096-019-00919-y","article-title":"Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis","volume":"41","author":"Zhao","year":"2019","journal-title":"Int J. Clin. Pharm."},{"key":"10.1016\/j.toxlet.2026.111893_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0378-4347(00)83212-0","article-title":"Quantitation of trans-10,11-dihydroxy-10,11-dihydrocarbamazepine in human urine by high-performance liquid chromatography","volume":"415","author":"Robbins","year":"1987","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"6","key":"10.1016\/j.toxlet.2026.111893_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1134\/S1061934823060096","article-title":"Highly Sensitive Determination of Carbamazepine and Oxcarbazepine and Identification of Their Degradation Products in Material Evidences and Human Cadaveric Liver by Gas Chromatography\u2013Mass Spectrometry","volume":"78","author":"Pirogov","year":"2023","journal-title":"J. Anal. Chem."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib23","first-page":"275","article-title":"Characterization of the Metabolites of Carbamazepine in Patient Urine by Liquid Chromatography\/Mass Spectrometry","volume":"25","author":"Maggs","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.toxlet.2014.10.012","article-title":"Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury","volume":"232","author":"Sasaki","year":"2015","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.toxlet.2026.111893_bib25","unstructured":"Levetiracetam. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed November 24, 2025. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548785\/\u3009."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.toxlet.2026.111893_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.21536","article-title":"Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor","volume":"45","author":"Cerec","year":"2007","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.toxlet.2026.111893_bib28","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.1912","article-title":"BODIPY 493\/503 staining of neutral lipid droplets for microscopy and quantification by flow cytometry","volume":"6","author":"Qiu","year":"2016","journal-title":"Bio Protoc."},{"key":"10.1016\/j.toxlet.2026.111893_bib29","article-title":"A case of fatal acebutolol poisoning: an illustration of the potential of molecular networking","author":"Le Dar\u00e9","year":"2019","journal-title":"Int. J. Leg. Med."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77106-x","article-title":"New insights into quetiapine metabolism using molecular networking","volume":"10","author":"Le Dar\u00e9","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2026.111893_bib31","unstructured":"MassBank. Accessed January 10, 2026a. \u3008https:\/\/massbank.eu\/MassBank\/RecordDisplay?id=MSBNK-Athens_Univ-AU112002\u3009."},{"key":"10.1016\/j.toxlet.2026.111893_bib32","unstructured":"MassBank. Accessed January 10, 2026b. \u3008https:\/\/massbank.eu\/MassBank\/RecordDisplay?id=MSBNK-Waters-WA002905\u3009."},{"issue":"15","key":"10.1016\/j.toxlet.2026.111893_bib33","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1021\/ac030082k","article-title":"Determination of Carbamazepine and Its Metabolites in Aqueous Samples Using Liquid Chromatography\u2212Electrospray Tandem Mass Spectrometry","volume":"75","author":"Miao","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.toxlet.2026.111893_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115017","article-title":"Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS\/MS in epileptic patients","volume":"220","author":"Yang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"14","key":"10.1016\/j.toxlet.2026.111893_bib35","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jssc.202200025","article-title":"A sensitive LC-MS\/MS method for quantification of phenytoin and its major metabolite with application to in vivo investigations of intravenous and intranasal phenytoin delivery","volume":"45","author":"Prentice","year":"2022","journal-title":"J. Sep Sci."},{"issue":"11","key":"10.1016\/j.toxlet.2026.111893_bib36","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jps.2600661124","article-title":"Identification of Urinary Catechol and Methylated Catechol Metabolites of Phenytoin in Humans, Monkeys, and Dogs by GLC and GLC-Mass Spectrometry","volume":"66","author":"Midha","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2026.111893_bib37","unstructured":"Humans IWG on the E of CR to. Phenytoin. In: Some Pharmaceutical Drugs. International Agency for Research on Cancer; 1996. Accessed January 16, 2026. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK423938\/\u3009."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jpba.2008.05.035","article-title":"Quantification of levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: application to therapeutic drug monitoring","volume":"48","author":"Matar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s43094-021-00347-8","article-title":"Characterization and In-silico toxicity prediction of degradation products of felbamate","volume":"7","author":"Chodankar","year":"2021","journal-title":"Futur J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.558","article-title":"Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: a pilot study in healthy volunteers","volume":"8","author":"Dao","year":"2020","journal-title":"Pharm. Res Perspect."},{"issue":"14","key":"10.1016\/j.toxlet.2026.111893_bib41","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/rcm.2012","article-title":"Liquid chromatography\/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma","volume":"19","author":"Ramakrishna","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/dta.3362","article-title":"Valproic acid determination by liquid chromatography coupled to mass spectrometry (LC\u2013MS\/MS) in whole blood for forensic purposes","volume":"15","author":"Pascali","year":"2023","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2025.102529","article-title":"Mitochondrial dysfunction in drug-induced hepatic steatosis: Recent findings and current concept","volume":"49","author":"Borgne-Sanchez","year":"2025","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"key":"10.1016\/j.toxlet.2026.111893_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","article-title":"Drug-induced liver injury in obesity and nonalcoholic fatty liver disease","volume":"85","author":"Allard","year":"2019","journal-title":"Adv. Pharm."},{"issue":"19","key":"10.1016\/j.toxlet.2026.111893_bib45","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.3390\/ijms231911428","article-title":"Vitro Models for Studying Chronic Drug-Induced Liver Injury","volume":"23","author":"Donato","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.toxlet.2026.111893_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2010.11.006","article-title":"Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver","volume":"54","author":"Begriche","year":"2011","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.toxlet.2026.111893_bib49","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.toxlet.2026.111893_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1983.tb01537.x","article-title":"Hepatic toxicity of antiepileptic drugs: a review","volume":"68","author":"Gram","year":"1983","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pharmtox-030220-015007","article-title":"Models of idiosyncratic drug-induced liver injury","volume":"61","author":"Yokoi","year":"2021","journal-title":"Annu Rev. Pharm. Toxicol."},{"issue":"11","key":"10.1016\/j.toxlet.2026.111893_bib52","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharm."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.07.071","article-title":"Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease","volume":"571","author":"V\u00e1clav\u00edkov\u00e1","year":"2015","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/bmme.1995.1069","article-title":"Induction of microsomal epoxide hydrolase activity in inbred mice by chronic phenytoin exposure","volume":"56","author":"Hartsfield","year":"1995","journal-title":"Biochem. Mol. Med."},{"issue":"8-9","key":"10.1016\/j.toxlet.2026.111893_bib55","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur. J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.toxlet.2026.111893_bib56","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.28472","article-title":"Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib57","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.celrep.2016.12.070","article-title":"Human Carboxylesterase 2 reverses obesity-induced diacylglycerol accumulation and glucose intolerance","volume":"18","author":"Ruby","year":"2017","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.toxlet.2026.111893_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/bms.1200040415","article-title":"Hydantoin ring glucuronidation: characterization of a new metabolite of 5,5-diphenylhydantoin in man and the rat","volume":"4","author":"Smith","year":"1977","journal-title":"Biomed. Mass Spectrom."},{"issue":"5","key":"10.1016\/j.toxlet.2026.111893_bib59","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/dmdi-2013-0046","article-title":"Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response","volume":"29","author":"Jaramillo","year":"2014","journal-title":"Drug Metab. Drug Inter."},{"issue":"10","key":"10.1016\/j.toxlet.2026.111893_bib61","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3390\/s19102245","article-title":"Cytochrome P450 1A1\/2, 2B6 and 3A4 HepaRG Cell-Based Biosensors to Monitor Hepatocyte Differentiation, Drug Metabolism and Toxicity","volume":"19","author":"Vlach","year":"2019","journal-title":"Sensors"},{"issue":"7","key":"10.1016\/j.toxlet.2026.111893_bib62","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.2012.685159","article-title":"The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human","volume":"8","author":"Andersson","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/ijms23010082","article-title":"Molecular networking for drug toxicities studies: the case of hydroxychloroquine in COVID-19 patients","volume":"23","author":"Ferron","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.toxlet.2026.111893_bib64","article-title":"Use of innovative, cross-disciplinary in vitro, in silico and in vivo approaches to characterize the metabolism of chloro-alpha-pyrrolidinovalerophenone (4-Cl-PVP)","author":"Pelletier","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2026.111893_bib65","article-title":"Metabolite elucidation of 2-fluoro-deschloroketamine (2F-DCK) using molecular networking across three complementary in vitro and in vivo models","author":"Gicquel","year":"2021","journal-title":"Drug Test. Anal."},{"issue":"12","key":"10.1016\/j.toxlet.2026.111893_bib66","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3390\/pharmaceutics14122665","article-title":"A Transversal Approach Combining In Silico, In Vitro and In Vivo Models to Describe the Metabolism of the Receptor Interacting Protein 1 Kinase Inhibitor Sibiriline","volume":"14","author":"Pelletier","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00204-023-03617-x","article-title":"silico and in vitro metabolism studies of the new synthetic opiate AP-237 (bucinnazine) using bioinformatics tools","volume":"98","author":"Pelletier","year":"2024","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/pharmaceutics13020270","article-title":"Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug\u2013Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach","volume":"13","author":"Fuhr","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2010.04.013","article-title":"HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro","volume":"63","author":"L\u00fcbberstedt","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"6","key":"10.1016\/j.toxlet.2026.111893_bib70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1124\/dmd.107.019901","article-title":"Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies","volume":"36","author":"Joss\u00e9","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.toxlet.2026.111893_bib71","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1124\/dmd.114.058123","article-title":"Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells","volume":"42","author":"Bachour-El Azzi","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.toxlet.2026.111893_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2015.981523","article-title":"Human induced pluripotent stem cell-derived hepatocytes for toxicology testing","volume":"11","author":"Mann","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.toxlet.2026.111893_bib73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","article-title":"The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics","volume":"39","author":"Mamiya","year":"1998","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.toxlet.2026.111893_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C9 gene","volume":"33","author":"Schwarz","year":"2003","journal-title":"Eur. J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.toxlet.2026.111893_bib75","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427426000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:22:38Z","timestamp":1776752558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427426000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"alternative-id":["S0378427426000767"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.111893","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of hepatic steatosis on antiseizure drug metabolism: in vitro evidence from differentiated HepaRG cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2026.111893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111893"}}